Sanofi

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Sanofi Sees Global Vaccine Sales Doubling: Report

NEW YORK (Reuters) - Sanofi-Aventis SA SASY expects global vaccine sales to double to 22 billion euros ($34 billion) by 2016 and will invest 4 billion euros by then to expand its production capacity to meet rising demand, the head of...

Tags: HEALTHCARE, vaccine, Sanofi-Aventis, sales, class action, New York, Thomson Reuters Corp.

News items 2008-06-25

Additional Resources

Sanofi-Aventis bids 1.65 billion euros for control of Zentiva

PRAGUE AFP — French pharmaceutical group Sanofi-Aventis launched a bid worth 1.655 billion euros (2.6 billion dollars) for the 74.12 percent of Czech company Zentiva it does not already own on Friday. But the Zentiva board immediately urged shareholders to wait before taking any action. The...

Articles 2008-07-11

Silence Therapeutics Announces Successful Opposition of Glover Patent

LONDON, July 11 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN), a leading European RNA interference RNAi focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the...

Articles 2008-07-11

Danish biopharmaceutical company Bavarian Nordic A/S files patent infringement suit against Oxford BioMedica Plc

NORDIC BUSINESS REPORT-1 July 2008-Danish biopharmaceutical company Bavarian Nordic A/S files patent infringement suit against Oxford BioMedica PlcC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Danish biopharmaceutical company Bavarian Nordic A/S (OMX Copenhagen: BAVA) said on Monday (30 June) that it has filed a patent infringement suit against the UK company...

Articles 2008-07-01

Pertussis surveillance in private pediatric practices, France, 2002-2006

To the Editor: In France, pertussis epidemiology has been extensively studied since 1993. Immunization of children with a highly efficacious pertussis whole-cell Pw vaccine (Sanofi Pasteur MSD, Lyon, France) for 40 years (since 1966) has reduced the incidence of pertussis. It has been demonstrated that infectious or vaccinal immunity to...

Articles 2008-07-01

Bevil Joins Varsity Sports Media as Vice President of Sales

KNOXVILLE, Tenn. -- Chris Bevil has been named vice president of sales for Varsity Sports Media VSM. Bevil will be based in Knoxville, where he will be responsible for all sales management duties for VSM, and will work closely with Craig Baroncelli, VSM general manager and publisher, on marketing strategies...

Articles 2008-06-30

A New Citeline Analysis Provides Valuable Clues to Health of Drug Companies

Report in Good Clinical Practice Journal GCPj Finds That Novartis Leads the Pack for Ongoing Trials in Autoimmune, Cardiovascular, and Metabolic Diseases Sanofi-aventis Takes the Top Rank for Ongoing Oncology Trials NEW YORK, June 30 /PRNewswire/ -- In a new Expert Analysis article published in...

Articles 2008-06-30

Rabies vaccine runs out

HEALTH chiefs are on rabies alert as supplies of vaccine for the deadly virus have almost run out. British holidaymakers are being warned to take extra care as a global shortage has led to severe restrictions on injections. The only two suppliers...

Articles 2008-06-29

Federal Advisory Committee Votes to Include Newly Licensed Pentacel® Vaccine in Vaccines for Children Program

- New combination vaccine offers good fit to childhood immunization schedule providing protection with fewer shots - SWIFTWATER, Pa., June 26 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that its PentacelR, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and...

Articles 2008-06-26

A Competitor Analysis of the Antihypertensives Market Including Detailed Market Information and Major Companies Active in the Industry

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/1d8ee0/competitor_analysi) has announced the addition of the "Competitor Analysis: Antihypertensives" report to their offering. The Competitive Intelligence Report Antihypertensives as of June 2008 provides a competitor analysis in the development pipeline of novel treatments of pulmonary artery hypertension, arterial hypertension, portal hypertension...

Articles 2008-06-25

Unity Square in New Brunswick Receives Historic Contribution Through NJ Neighborhood Revitalization Tax Credit Program

NEW BRUNSWICK, N.J., June 24 /PRNewswire/ -- NJ Department of Community Affairs is pleased to announce that sanofi-aventis allocates $1,000,000 to the Neighborhood Revitalization Tax Credit Program, NJ Department of Community Affairs. This is the largest contribution committed to one nonprofit organization since the inception of the New Jersey...

Articles 2008-06-24

New 5-in-1 Vaccine May Reduce Number of Pediatric Shots

The U.S. Food and Drug Administration has approved Sanofi Pasteur's Pentacel combination vaccine for children, the company said Monday. from 23 shots to 16, Sanofi said in a statement. The vaccine was clinically tested among more than 5,000 children. Adverse reactions included injection site redness, swelling, fever, fussiness, and crying....

Articles 2008-06-23

U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel®

- PentacelR vaccine is the first 5-in-1 pediatric combination for immunization against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b Hib - SWIFTWATER, Pa. and LYON, France, June 23 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food...

Articles 2008-06-23

Sanofi strikes back in takeover battle for big Czech drug company

PRAGUE AFP — Czech-based generic drugs giant Zentiva was at the heart of a takeover tussle Wednesday after French group Sanofi-Aventis struck back with an offer countering a bid by local financial concern PPF. PPF, holding a 19.2 percent stake in Zentiva, which has substantial markets in Slovakia,...

Articles 2008-06-18

Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services

NEW YORK, June 17 /PRNewswire/ -- Among US primary care physicians, Novartis earns the highest sales rep relationship scores, followed by Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new research from TNS Healthcare. Novartis also takes the top spot in Europe, demonstrating a consistent ability to build strong...

Articles 2008-06-17

Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide® Tablets

PITTSBURGH, June 16 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received tentative approval from the U.S. Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Irbesartan and Hydrochlorothiazide Tablets, 150 mg/12.5 mg and 300 mg/12.5 mg. ...

Articles 2008-06-16

European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals

Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing Gastrointestinal Side Effects of Antiplatelet Therapy MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its...

Articles 2008-06-16

Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile

LYON, France and SWIFTWATER, Pa., June 16 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today its commitment to donate 60 million doses of H5N1 vaccine to the World Health Organization WHO over 3 years for the establishment of an H5N1 vaccine global stockpile. ...

Articles 2008-06-16

Cancer Vaccine Research Is Coming To Fruition, With A Number Of Products Now In Phase III Trials And 15 Therapeutic Cancer Vaccines Realistically Expected To Launch By 2013

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/eb249c/cancer_vaccine_dev) has announced the addition of the "Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker" report to their offering. The launch of Sanofi Pasteur MSD's Gardasil and GSK's Cervarix has propelled cancer vaccines from research obscurity to a key area of...

Articles 2008-06-11

Ambien CR® CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder

Ambien CRR 12.5 mg significantly improved sleep onset, sleep maintenance and total sleep time compared to placebo BRIDGEWATER, N.J., June 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today results from a new study that showed Ambien CRR (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep...

Articles 2008-06-10